HC Wainwright Predicts Cytosorbents FY2028 Earnings

Cytosorbents Co. (NASDAQ:CTSO - Free Report) - Research analysts at HC Wainwright issued their FY2028 EPS estimates for shares of Cytosorbents in a report released on Thursday, April 3rd. HC Wainwright analyst S. Lee forecasts that the medical research company will post earnings per share of ($0.07) for the year. HC Wainwright currently has a "Neutral" rating and a $1.00 target price on the stock. The consensus estimate for Cytosorbents' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents' FY2029 earnings at ($0.05) EPS.

Several other equities analysts have also issued reports on CTSO. StockNews.com began coverage on shares of Cytosorbents in a report on Thursday, April 3rd. They issued a "hold" rating for the company. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Cytosorbents has a consensus rating of "Moderate Buy" and an average price target of $4.67.

Cytosorbents Trading Down 2.6 %

NASDAQ CTSO traded down $0.03 during trading on Friday, reaching $0.94. 45,036 shares of the stock traded hands, compared to its average volume of 143,301. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The firm has a market cap of $58.44 million, a price-to-earnings ratio of -2.60 and a beta of 1.17. The stock's 50-day moving average price is $1.06 and its 200 day moving average price is $1.03.

Remove Ads

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The firm had revenue of $9.20 million for the quarter, compared to analysts' expectations of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%.

Institutional Investors Weigh In On Cytosorbents

Several large investors have recently made changes to their positions in CTSO. Avenir Corp boosted its stake in Cytosorbents by 4.0% in the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after purchasing an additional 118,387 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Cytosorbents during the fourth quarter worth about $99,000. Millennium Management LLC bought a new position in shares of Cytosorbents during the fourth quarter worth about $30,000. Geode Capital Management LLC raised its position in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after buying an additional 32,415 shares during the last quarter. Finally, Skylands Capital LLC lifted its stake in Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock valued at $2,531,000 after acquiring an additional 26,195 shares in the last quarter. Institutional investors own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.